These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30867656)

  • 1. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis.
    Bayón JC; Orruño E; Portillo MI; Asua J
    Cost Eff Resour Alloc; 2019; 17():6. PubMed ID: 30867656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.
    Morris S; Karlsen S; Chung N; Hill M; Chitty LS
    PLoS One; 2014; 9(4):e93559. PubMed ID: 24714162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic evaluation of noninvasive prenatal testing and serum screening for down syndrome.
    Xiao G; Zhao Y; Huang W; Hu L; Wang G; Luo H
    PLoS One; 2022; 17(4):e0266718. PubMed ID: 35421148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.
    Chitty LS; Wright D; Hill M; Verhoef TI; Daley R; Lewis C; Mason S; McKay F; Jenkins L; Howarth A; Cameron L; McEwan A; Fisher J; Kroese M; Morris S
    BMJ; 2016 Jul; 354():i3426. PubMed ID: 27378786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China.
    Xu Y; Wei Y; Ming J; Li N; Xu N; Pong RW; Chen Y
    Int J Technol Assess Health Care; 2019 Jan; 35(3):237-242. PubMed ID: 31131776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey.
    Ökem ZG; Örgül G; Kasnakoglu BT; Çakar M; Beksaç MS
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():40-44. PubMed ID: 29040895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.
    Zhang W; Mohammadi T; Sou J; Anis AH
    PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.
    García-Pérez L; Linertová R; Álvarez-de-la-Rosa M; Bayón JC; Imaz-Iglesia I; Ferrer-Rodríguez J; Serrano-Aguilar P
    Eur J Health Econ; 2018 Sep; 19(7):979-991. PubMed ID: 29249015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis.
    Shang W; Wan Y; Chen J; Du Y; Huang J
    BMJ Open; 2021 Jul; 11(7):e046582. PubMed ID: 34230019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis.
    Nshimyumukiza L; Beaumont JA; Duplantie J; Langlois S; Little J; Audibert F; McCabe C; Gekas J; Giguère Y; Gagné C; Reinharz D; Rousseau F
    J Obstet Gynaecol Can; 2018 Jan; 40(1):48-60. PubMed ID: 28784564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program.
    Ayres AC; Whitty JA; Ellwood DA
    Aust N Z J Obstet Gynaecol; 2014 Oct; 54(5):412-7. PubMed ID: 25196262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.
    Neyt M; Hulstaert F; Gyselaers W
    BMJ Open; 2014 Nov; 4(11):e005922. PubMed ID: 25380810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21.
    Wang S; Liu K; Yang H; Ma J
    Front Public Health; 2022; 10():870543. PubMed ID: 35712262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of cell-free DNA-based non-invasive prenatal testing in a National Health Service Regional Genetics Laboratory.
    Togneri FS; Kilby MD; Young E; Court S; Williams D; Griffiths MJ; Allen SK
    Genet Res (Camb); 2019 Dec; 101():e11. PubMed ID: 31813398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.
    O'Leary P; Maxwell S; Murch A; Hendrie D
    Aust N Z J Obstet Gynaecol; 2013 Oct; 53(5):425-33. PubMed ID: 24090461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population.
    Kostenko E; Chantraine F; Vandeweyer K; Schmid M; Lefevre A; Hertz D; Zelle L; Bartha JL; Di Renzo GC
    Fetal Diagn Ther; 2019; 45(6):413-423. PubMed ID: 30130800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States.
    Walker BS; Nelson RE; Jackson BR; Grenache DG; Ashwood ER; Schmidt RL
    PLoS One; 2015; 10(7):e0131402. PubMed ID: 26133556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis.
    Fairbrother G; Burigo J; Sharon T; Song K
    J Matern Fetal Neonatal Med; 2016; 29(7):1160-4. PubMed ID: 26000626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.